期刊文献+

蛋白Artemin在三阴性和非三阴性乳腺癌组织中的表达及其意义 被引量:1

Expression and Clinical Significance of Artemin Protein in Triple-negative and Nontriple-negative Breast Cancer Tissues
下载PDF
导出
摘要 目的研究蛋白Artemin在三阴性(triple-negative breast cancer,TNBC)和非三阴性(non-triplenegative breast cancer,non-TNBC)乳腺癌组织中的表达情况,进一步探索蛋白Artemin与乳腺癌临床病理及预后的关系,为临床判断其生物学行为及评估预后提供有力证据。方法回顾性分析2005年7月至2009年7月间河北医科大学附属沧州市中心医院收治的乳腺癌患者,根据入选标准,随机抽取三阴性及非三阴性乳腺癌各120例作为研究对象。运用统计学方法对所有数据进行t检验、χ2检验,生存分析采用寿命表法、Kaplan-Meier曲线,Cox比例风险模型进行检验。结果蛋白Artemin阳性率为61.7%(148/240),在TNBC中的阳性率为82.5%(99/120),明显高于non-TNBC中的阳性率41.0%(49/120);在TNBC组中蛋白Artemin阳性与阴性的患者1、3、5年生存率分别为93.0%、78.0%、50.0%vs.100.0%、89.0%、79.0%;non-TNBC组中蛋白Artemin阳性与阴性的患者1、3、5年生存率分别为98.0%、89.0%、89.0%vs.99.0%、97.0%、97.0%,差异具有统计学意义(P<0.05)。结论蛋白Artemin在TNBC乳腺癌中的表达明显高于non-TNBC,生存率明显降低,是判断乳腺癌恶性程度的重要指标,值得推广研究。 Objective To investigate the expression of Artemin protein in triple-negative breast cancer(TNBC) and non-triple-negative breast cancer(non-TNBC) tissues, and to further explore its relationship with clinical pathology and the prognosis of tumor, to provide powerful evidence for judging biological behaviour and evaluating the prognosis. Methods According to the criteria, 240 cases of breast cancer(120 cases of TNBC, 120 cases of non-TNBC, respectively) were selected randomly and admitted to Cangzhou Central Hospital of Hebei Medical University from July 2005 to July 2009. The expression of Artemin was detected in tumor tissues. All data were analyzed using t test and chi-square test, and the survival of patients was analyzed using the life table and Kaplan-Meier curves. The COX proportional hazards model was also used for the prognosis. Results The positive expression rate of Artemin protein was 61.7%(148/240). The positive rate of Artemin in TNBC tissues was higher than that in non-TNBC tissues [82.5%(99/120) vs. 41.0%(49/120)]. The survival rates of 1-, 3-, 5-year in the groups of TNBC with positive Artemin, TNBC without Artemin, non-TNBC with positive Artemin, and non-TNBC without Artemin were 93.0%, 78.0%, 50.0% vs. 100.0%, 89.0%, 79.0% vs. 98.0%, 89.0%, 89.0% vs. 99.0%, 97.0%, 97.0%, respectively(P〈0.05). Conclusion Artemin is clearly expressed higher in TNBC than non-TNBC tissues, and is one of the important indicators for the prognosis of breast cancer, with great value for research.
出处 《肿瘤防治研究》 CAS CSCD 北大核心 2016年第6期479-482,共4页 Cancer Research on Prevention and Treatment
关键词 乳腺癌 ARTEMIN 免疫组织化学 预后 Breast cancer Artemin Immunohistochemistry Prognosis
  • 相关文献

参考文献7

二级参考文献79

  • 1Aksoy S,Dizdar O,Harputluoglu H,et al.Demographic,clinical,and pathological characteristics of Turkish triple-negative breast cancer patients:single center experience[J].Ann Oncol,2007,18(11):1904-1906.
  • 2Carey LA,Perou CM,Livasy CA,et al.Race,breast cancer subtypes,and survival in the Carolina Breast Cancer Study[J].JAMA,2006,295(21):2492-2502.
  • 3Dent R,Trudeau M,Pritchard KI,et al.Triple-negative breast cancer; Clinical features and patterns of recurrence[J].Clin Cancer Res,2007,13(15):4429-4434.
  • 4Haffty BG,Yang Q,Reiss M,et al.Locoregional relapse and distant metastasis in conservatively managed triple negative early stage breast cancer[J].J Clin Oncol,2006,24(36):5652-5657.
  • 5Dent R,Hanna WM,Trudeau M,et al.Pattern of metastatic spread in triple-negative breast cancer[J].Breast Cancer Res Treat,2009,115(2):423-428.
  • 6Torrisi R,Balduzzi A,Ghisini R,et al.Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin,cisplatin,and infusional fluorouracil followed by weekly paclitaxe[J].Cancer Chemother Pharmacol,2008,62(4):667-672.
  • 7Sirohi B,Arnedos M,Popat S,et al.Platinum-based chemotherapy in triple-negative breast cancer[J].Ann Oncol,2008,19 (11):1847-1852.
  • 8Scrlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci, 2001, 98: 10869- 10874.
  • 9Dent R, Trudean M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res ,2007,13:4429-4434.
  • 10Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA, 2006,295:2492-2502.

共引文献228

同被引文献20

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部